128 results
Page 2 of 7
F-3
EX-5.1
9suty9da0u
30 Jun 23
Shelf registration (foreign)
4:06pm
F-3
EX-4.2
qfy s3pxw
30 Jun 23
Shelf registration (foreign)
4:06pm
F-3
EX-5.2
nustxyv1f
30 Jun 23
Shelf registration (foreign)
4:06pm
F-3
mtqnr0g5kzbcmku nf
30 Jun 23
Shelf registration (foreign)
4:06pm
6-K
EX-99.1
ikql6cexsfsyoo2c6m
21 Jun 23
InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients
8:30am
6-K
EX-99.2
ula4n4f 1apkr
11 May 23
Current report (foreign)
8:00am
6-K
EX-99.1
a6pnzep
11 May 23
Current report (foreign)
8:00am
6-K
EX-1.1
bf0t wdsug
13 Apr 23
Current report (foreign)
4:01pm
6-K
EX-5.1
t6tmicpj
13 Apr 23
Current report (foreign)
4:01pm
424B5
ujoi3ti xx0lxl7ncr
13 Apr 23
Prospectus supplement for primary offering
8:48am
424B5
1rh00bh5
11 Apr 23
Prospectus supplement for primary offering
4:11pm
6-K
EX-99.1
i1n8lgr8iyc489
5 Apr 23
Current report (foreign)
4:01pm
6-K
EX-99.1
q7sq5az lw
4 Apr 23
InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients
4:50pm
6-K
EX-99.4
zm9to0g8mlu7fp23c 5b
9 Nov 22
Current report (foreign)
7:52am
6-K
EX-99.2
4avbtvjuv44l9
9 Nov 22
Current report (foreign)
7:52am
6-K
EX-99.1
jkcy 08wvetiszh7
8 Sep 22
InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine
8:00am
6-K
EX-99.2
fzeafp
5 Aug 22
Current report (foreign)
6:07am
6-K
EX-99.3
gf9jv7r
5 Aug 22
Current report (foreign)
6:07am
6-K
EX-99.1
un50hyk
12 May 22
Current report (foreign)
8:30am
6-K
EX-99.3
jnoomond 9o7qz0w
12 May 22
Current report (foreign)
8:30am